Repare Therapeutics Out-Licenses its Discovery Platforms to DCx Biotherapeutics
Shots:
- Repare has out-licensed its discovery platform incl. SNIPRx, SNIPRx-surf, & STEP2 , along with certain intellectual property to DCx
- As per the deal, Repare will get $4M as upfront & near-term payments, 9.99% equity in DCx with dilution protection, & future potential out-licensing, clinical & commercial milestones, with low-single digit tiered sales royalties; Repare will also get a board nominee seat in DCx
- Under the deal, DCx will retain ~20 Repare’s staff & acquire lease rights to certain laboratory facilities in Montreal, plus acquire certain laboratory equipment
Ref: Repare Therapeutics | Image: Repare Therapeutics & DCx Biotherapeutics
Related News:- Repare Therapeutics Reports the P-I (MYTHIC) Trial Data of Lunresertib Plus Camonsertib to Treat Gynecologic Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
